literature

HIV mutation literature information.

Update of the drug resistance mutations in HIV-1: December 2010.

PMID: 21245516 2010 Topics in HIV medicine

Abstract: The mutations I13V, K20M/R, E35G, and L90M were removed from the tipranavir/ritonavir bar, reflecting new understanding.

Patients with discordant responses to antiretroviral therapy have impaired killing of HIV-infected T cells.

PMID: 21124822 2010 PLoS pathogens

Method: K20R sense: 5'-GGGCAACTAAGGGAAGCTCTA-3', anti-sense: 5'-TAGAGCTTCCCTTAGTTGCCC-3'; D25G sense: 5'-AGGAAGCTCTATTAGGTACAGGAGCAGATGA-3', anti-sense: 5'-TCATCTGCTCCTGTACCTAATAGAGCTTCCT; T26S sense: 5'-GAAGCTCTATTAGATAGTGGAGCAGATGATACA-3'; anti-sense: 5'-TGTATCATCTGCTCCACTATCTAATAGAGCTTC-3'; I54V sense: 5'-GGAATTGGAGGTCTTATCAAAGTAAGA-3; anti-sense: 5'-TCTTACTTTGATAAGACCTCCAATTCC-3'; I54V sense: 5'-ATTGGAGGTTTTGTCAAAGTAAGACAG-3', anti-sense: 5'-CTGTCTTACTTTGACAAAACCTCCAAT-3'; L63P sense: 5'-GTAAGACAGTATGATCAGATACCCATAGAAATCTGTGGAC-3'; anti-sense: 5'-GTCCACAGATTTCTATGGGTATCTGATCATACTGTCTTAC-3'; V82A sense: 5'-GTAGGACCTACACCTGCCAACATAATTGGAAG-3'; anti-sense: CTTCCAATTATGTTGGCAGGTGTAGGTCCTAC-3'; L90M sense: 5'-TAATTGGAAGAAATCTGATGA

Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study.

PMID: 20532178 2010 PloS one

Table: K20R

Protease polymorphisms in HIV-1 subtype CRF01_AE represent selection by antiretroviral therapy and host immune pressure.

PMID: 20009919 2010 AIDS (London, England)

Abstract: Three polymorphisms (L10 V, K20RMI and I62 V) were associated with the presence of a major PRAM (P < 0.05).

Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania.

PMID: 19583845 2009 BMC infectious diseases

Table: K20R

HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme.

PMID: 19578237 2009 Antiviral therapy

Discussion: The impact of these on viral drug susceptibility is uncertain, but many, including L10I/V, K20R, M36I, L63P, A71V/T and V77I, are not expected to cause major drug resistance.

Role of atazanavir in the treatment of HIV infection.

PMID: 19436623 2009 Therapeutics and clinical risk management

Introduction: Mutations more significant to be included in the GIQ model are the following: L10F/I/V, K20M/R, L24I, D30N, V32I, L33F, M36I/L, I47V/A, G48V, I50V, I50L, F53L, I54V/L/A/M/T/S, L63P, A71V/T, G73S, V77I, V82A/F/T, I84V, N88D/S and

Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, Uganda.

PMID: 19276794 2009 AIDS (London, England)

Table: K20K/R

Table: K20R

Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure.

PMID: 18992847 2009 Infection, genetics and evolution

Abstract: In untreated patients, mutations L10V, K20R, and M36I were more frequent in subtype F1, while L63P, A71T, and V77I were more prevalent in subtype B.

Method: Mutations L10F/I/R/V, K20M/R, L24I, L33F, M36I, F53L, I54V/L/A/M/T/S, L63P, A71V/T, G73C/S/T/A, V77I and N88D/S were considered as minor resist

Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase.

PMID: 18271957 2008 Retrovirology

Introduction: These mutations include the K20R, V35M, T39A, E40F, K43E/Q/N, A98G, K122E, G196E, E203K/D, H208Y, D218E, H221Y, K223E/Q and L228H/R changes.

Browser Board

Co-occurred Entities

Filtrator